JP5934719B2 - 薬物懸濁液の調製におけるクロスフロー濾過を用いた液体培地交換の使用 - Google Patents

薬物懸濁液の調製におけるクロスフロー濾過を用いた液体培地交換の使用 Download PDF

Info

Publication number
JP5934719B2
JP5934719B2 JP2013548820A JP2013548820A JP5934719B2 JP 5934719 B2 JP5934719 B2 JP 5934719B2 JP 2013548820 A JP2013548820 A JP 2013548820A JP 2013548820 A JP2013548820 A JP 2013548820A JP 5934719 B2 JP5934719 B2 JP 5934719B2
Authority
JP
Japan
Prior art keywords
suspension
liquid medium
drug
diafiltration
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013548820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502624A (ja
JP2014502624A5 (enExample
Inventor
ニーデルマン，ハンス・ペーター
ボーテ，ヘイコ
Original Assignee
インターベット インターナショナル ベー． フェー．
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー．, インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2014502624A publication Critical patent/JP2014502624A/ja
Publication of JP2014502624A5 publication Critical patent/JP2014502624A5/ja
Application granted granted Critical
Publication of JP5934719B2 publication Critical patent/JP5934719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
JP2013548820A 2011-01-12 2012-01-11 薬物懸濁液の調製におけるクロスフロー濾過を用いた液体培地交換の使用 Active JP5934719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431942P 2011-01-12 2011-01-12
US61/431,942 2011-01-12
PCT/EP2012/050336 WO2012095439A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Publications (3)

Publication Number Publication Date
JP2014502624A JP2014502624A (ja) 2014-02-03
JP2014502624A5 JP2014502624A5 (enExample) 2015-02-26
JP5934719B2 true JP5934719B2 (ja) 2016-06-15

Family

ID=45478323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548820A Active JP5934719B2 (ja) 2011-01-12 2012-01-11 薬物懸濁液の調製におけるクロスフロー濾過を用いた液体培地交換の使用

Country Status (10)

Country Link
US (1) US9066864B2 (enExample)
EP (1) EP2663287A1 (enExample)
JP (1) JP5934719B2 (enExample)
CN (1) CN103347499B (enExample)
AU (1) AU2012206621B2 (enExample)
BR (1) BR112013016851B1 (enExample)
CA (1) CA2823972C (enExample)
MX (1) MX346749B (enExample)
SG (2) SG10201807631SA (enExample)
WO (1) WO2012095439A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478959B2 (ja) * 2016-09-07 2019-03-06 株式会社富士薬品 粒子含有組成物を製造するためのシステム及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790912B2 (ja) 1999-05-12 2011-10-12 メタボリックス，インコーポレイテッド ポリヒドロキシアルカノエートを精製するための方法
EP1225968B1 (en) 1999-09-17 2006-04-05 Alfa Laval Nakskov A/S A method and an apparatus for continuous cross-flow diafiltration
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
WO2003063877A1 (en) * 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
PL208585B1 (pl) * 2002-10-25 2011-05-31 Intervet Int Bv Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca cefquinom, sposób jej wytwarzania i zastosowanie cefquinomu
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CN102811743B (zh) * 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂

Also Published As

Publication number Publication date
US9066864B2 (en) 2015-06-30
CA2823972C (en) 2019-05-28
MX346749B (es) 2017-03-29
WO2012095439A1 (en) 2012-07-19
SG191963A1 (en) 2013-08-30
JP2014502624A (ja) 2014-02-03
US20130281425A1 (en) 2013-10-24
SG10201807631SA (en) 2018-10-30
EP2663287A1 (en) 2013-11-20
CN103347499B (zh) 2017-04-05
AU2012206621B2 (en) 2017-04-27
MX2013008118A (es) 2013-08-12
CN103347499A (zh) 2013-10-09
BR112013016851B1 (pt) 2021-08-31
CA2823972A1 (en) 2012-07-19
BR112013016851A2 (pt) 2016-10-04
AU2012206621A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
JP7203078B2 (ja) 粒子の連続製造方法
DK2830597T3 (en) Preparation of Approximately Monodisperse Particles Using Particle Size Reduction or Increase and Membrane Separation
JP6215051B2 (ja) 油、脂肪、水溶液または有機溶液中のカルボン酸を、マイクロ−またはナノエマルション化により、可溶化、分離、除去、および反応させるための装置および方法
JP5536654B2 (ja) 医療用複合有機化合物粉体、その製造方法ならびに懸濁液
CN103732318A (zh) 使用水力旋流器加工微球
EP2153260A1 (en) Composition comprising high concentration of biologically active molecules and processes for preparing the same
CN1780670A (zh) 反溶剂凝固方法
KR20040082395A (ko) 결정 입자 제조용 장치 및 방법
JP4560155B2 (ja) リボフラビンの精製および晶出方法
JP2004500985A (ja) 新規な結晶粒子製造方法
JP2014502624A (ja) 薬物懸濁液の調製におけるクロスフロー濾過を用いた液体培地交換の使用
Onesti et al. Continuous tangential flow filtration to isolate extracellular vesicles from dairy by-products
JP2023502412A5 (enExample)
CN113061199A (zh) 一种纳滤膜浓缩提取粗品肝素钠的工艺
WO2012095438A1 (en) Particles and suspensions of cephalosporin antibiotics
Markad et al. Review on: Solubility enhancement of poorly water soluble drugs
CN105477001B (zh) 一种积雪草酸氨丁三醇盐脂质纳米粒制剂及其制备方法
JPS63126511A (ja) クロスフロ−型精密濾過方法
HK1194749A (en) Device for filtration, drying and storage
WO2024110444A1 (en) Method for purification of a target product using affinity purification technology
AU2006212177A1 (en) Method of purifying a surfactant by ultrafiltration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160509

R150 Certificate of patent or registration of utility model

Ref document number: 5934719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250